Seeking Alpha
 

United Therapeutics Corporation (UTHR)

- NASDAQ
Show Summaries  |  Hide Summaries
  • Dec. 21, 2013, 5:46 PM
  • Dec. 9, 2013, 7:24 AM
  • Oct. 29, 2013, 6:09 AM
  • Oct. 29, 2013, 12:05 AM
  • Oct. 28, 2013, 5:30 PM
  • Jul. 25, 2013, 6:07 AM
    United Therapeutics (UTHR): Q2 EPS of $1.52 beats by $0.03. Revenue of $280.6M beats by $30.43M. (PR)
    | Comment!
  • Apr. 25, 2013, 3:46 PM
    United Therapeutics (UTHR -3%) slides after its Q1 EPS results missed Street expectations earlier today. Revenue increased by nearly $41M over the prior year the period, with growth in product revenues reflecting the continuing increase in the number of patients being treated, but expenses in both R&D and SG&A pressured bottom line performance.
    | Comment!
  • Apr. 25, 2013, 6:10 AM
    United Therapeutics (UTHR): Q1 EPS of $1.19 misses by $0.28. Revenue of $245.1M beats by $3.96M. (PR)
    | Comment!
  • Apr. 11, 2013, 11:15 AM
    United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells.
    | 1 Comment
  • Mar. 25, 2013, 9:10 AM
    Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%
    | Comment!
  • Mar. 25, 2013, 6:11 AM
    The FDA has again rejected United Therapeutics' (UTHR) Treprostinil oral treatment for treating for high blood pressure. United Therapeutics intends to immediately request an "end of review" meeting with the FDA to discuss the rejection. Shares -6.3% premarket. (previous) (PR)
    | Comment!
  • Feb. 26, 2013, 1:26 PM
    After a valliant fight, United Therapeutics (UTHR -0.9%) gives up the days gains to trade in the red after Brean Murray cuts the shares to Hold on the back of its Q4 results posted earlier. The stock has had a good run since plummeting in October of last year on the FDA's rejection of Treprostinil, gaining nearly 30% and presently testing a 2-year high.
    | Comment!
  • Feb. 26, 2013, 12:22 PM
    United Therapeutics (UTHR +0.3%) holds on to gains in a weak tape after reporting Q4 earnings that easily beat Street estimates this morning. Revenue increased across all product lines covering both chronic and life-threatening conditions. Gross margins declined to 84% from 87% however, largely due to inventory writedowns. The company reaffirms FY13 guidance bracketing estimates, expecting revenues to fall within a range of 5% above or below $1B. Analysts are looking for revenues of $993.85M.
    | Comment!
  • Feb. 26, 2013, 6:11 AM
    United Therapeutics (UTHR): Q4 EPS of $1.60 beats by $0.36. Revenue of $243.8M beats by $10.39M. (PR)
    | Comment!
  • Feb. 26, 2013, 12:05 AM
    Notable earnings before Tuesday’s open: AG, AKRX, AMED, AMT, AUXL, AZO, BMO, BYD, CBRL, CIE, CMLP, CRZO, ECL, EXPD, GTI, HD, HFC, M,MFA, PCS, RRD, RSH, SKS, SPRD, SRE, THC, TSL, UNFI, UTHR
    | Comment!
  • Feb. 25, 2013, 5:30 PM
    Notable earnings before Tuesday’s open: AG, AKRX, AMED, AMT, AUXL, AZO, BMO, BYD, CBRL, CIE, CMLP, CRZO, ECL, EXPD, GTI, HD, HFC, M,MFA, PCS, RRD, RSH, SKS, SPRD, SRE, THC, TSL, UNFI, UTHR
    | Comment!
Visit Seeking Alpha's
UTHR vs. ETF Alternatives
Company Description
United Therapeutics Corp is a biotechnology company. The Company is engaged in thedevelopment and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.